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Abstract 
Background: Disturbed cytokine production is thought to govern inflammation in asthma, which, in its turn, 
may lead to uncontrolled disease. The aim of this study was to assess the relationship between cytokine 
production from blood leucocytes and the level of asthma control.  
Methods: We compared the production of interleukin (IL)-4, IL-6, IL-10, interferon (IFN)-γ and tumour necrosis 
factor-α from peripheral blood leucocytes in non-atopic healthy subjects (n = 22), atopic non-asthmatics (n = 10), 
well-controlled asthmatics [Juniper asthma control questionnaire (ACQ) score <1.5; n = 20] and patients with 
uncontrolled asthma despite inhaled or oral corticoids (ACQ score >1.5; n = 20). Fifty microlitres of peripheral 
blood was incubated for 24 h with RPMIc, lipopolysaccharide (LPS; 1 ng/ml) or phytohaemagglutinin (1 µg/ml), 
and cytokines were measured by immunotrapping (ELISA).  
Results: Both controlled and uncontrolled asthmatics as well as atopic non-asthmatics spontaneously produced 
more IL-4 than non-atopic healthy subjects (p < 0.001). IL-4 production induced by LPS was significantly 
greater (p < 0.05) in both asthma groups compared to atopic non-asthmatics and non-atopic healthy subjects. By 
contrast, IFN-γ release induced by LPS was lower in uncontrolled asthmatics than in non-atopic healthy subjects 
(p < 0.05) and controlled asthmatics (p < 0.05). IL-10 release after LPS was greater in uncontrolled asthmatics 
than in atopic non-asthmatics (p < 0.05). No difference was observed regarding other cytokines.  
Conclusion: Blood cells from patients with difficult-to-control atopic asthma display highly skewed Th2 
cytokine release following LPS stimulation. 
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Introduction 
Human studies suggest that exposure to lipopolysaccharide (LPS) can influence the development and severity of 
asthma. Endotoxin is considered to have a dual role in asthma. While it may prevent the development of atopy 
when exposure occurs in early life [1], this bacterial product may worsen asthma control when inhaled by adult 
asthmatics in whom the disease is already well established [2]. 
Airway exposure to endotoxin is known to promote airway [3] and systemic [4] neutrophilic inflammation, but 
this bacterial compound has a broad range of activities in vitro. Endotoxin is a potent stimulus for the innate 
immune system and is able to activate both the mononuclear [5] and granulocyte fraction from blood leucocytes 
[6, 7]. Some studies have suggested that persistent, difficult-to-treat asthma may be linked to an impaired innate 
immunity favouring chronic infection [8]. 
Although pathological heterogeneity of the disease has been highlighted over the past years [9], asthma often 
features an airway eosinophilic inflammation [10,11] orchestrated by Th2 cytokines [12, 13]. Our recent study 
showed that uncontrolled asthma encountered in daily practice is associated with increased airway eosinophilic 
inflammation as compared to well-controlled asthma [14]. Whether this relationship is also observed at the 
systemic level has not been investigated. 
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The purpose of our study was to determine if there was any relationship between asthma control and cytokine 
production from blood leucocytes in response to endotoxin. Interleukin (IL)-4 and interferon (IFN)-γ were 
chosen as markers of the Th2/Th1 balance, tumour necrosis factor (TNF)-α and IL-10 as pro- and anti-
inflammatory cytokines, respectively [15], and IL-6 as a cytokine playing a role in the transition from innate 
towards adaptive immunity [16]. 
The present study was performed on atopic asthmatics recruited from our asthma clinic and classified into two 
subgroups according to their level of asthma control [controlled asthma, i.e. asthma control questionnaire (ACQ) 
score <1.5, and uncontrolled asthma, i.e. ACQ score ≥1.5]. 
In order to clarify the role of asthma versus atopy in cytokine production, asthmatics were compared to atopic 
non-asthmatics and non-atopic healthy subjects. 
Materials and Methods 
Study Design and Subject Characteristics 
Patient demographics and functional and treatment characteristics are given in table 1. The Juniper ACQ is 
known to have strong evaluative and discriminative properties and can be used with confidence to measure 
asthma control [17]. 
In this study, 20 controlled atopic asthmatics (ACQ score <1.5) were compared with 20 uncontrolled atopic 
asthmatics (ACQ score ≥1.5), 10 atopic non-asthmatics [grass pollen rhinitis studied out of season with a 
provocative concentration of methacholine producing a 20% fall in forced expiratory volume in 1 s (FEV1) 
(PC20M) >16 mg/ml] and 22 non-atopic healthy subjects. Patients were recruited from our asthma clinic at CHU 
Liege Sart-Tilman between January 2006 and June 2009, and the group of atopic non-asthmatics comprised 
subjects with asymptomatic rhinitis recruited from a database for a clinical trial on immunotherapy. 
All asthmatics were diagnosed on the basis of significant FEV1 reversibility (≥12% from baseline) with β2-
agonists or bronchial hyperresponsiveness to methacholine (PC20M <16 mg/ml). Atopy was defined as a 
positive skin prick test reaction (wheal ≥3 mm compared with control) to common aeroallergens, including 
house dust mites, cat and dog dander, grass, tree, pollen and moulds. 
The protocol was approved by the local ethics committee, and every subject gave written informed consent. 
Peripheral Blood Sampling and Cell Count 
Peripheral blood samples were collected in apyrogenic, heparinized tubes (Venosafe, Terumo®, Belgium). Total 
and differential blood cell counts were obtained with an Advia 210 automatic counter (USA). Counting and cell 
typing were based on flow cytometry with bidimensional volume distribution, peroxidase concentration and 
lobularity of leucocytes as parameters. 
Blood Cell Culture and Cytokine Assay 
Cytokines (IL-4, IL-6, IL-10, TNF-α, IFN-γ) were measured by a two-step sandwich-type immunoassay. The 
antibodies and standards were purchased from Biosource (Cytosets, Biosource, Invitrogen, Belgium). Fifty 
microlitres of standards or whole blood (diluted twice) was incubated at 37°C with 200 µl of Roswell Park 
Memorial Institute medium (RPMI)-1640 supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin 
(Cambrex, Verviers, Belgium) and 2% of inactivated fetal calf serum (Cambrex), or LPS (Salmonella enteridis, 
Sigma, St. Louis, Mo., USA; 1 ng/ml) or phytohaemagglutinin (PHA; Biochrom AG, Berlin, Germany; 1 µg/ml) 
in apyrogen microwells which had previously been coated with specific antibodies directed towards the chosen 
cytokines. 
After 24 h, the wells were washed and 100 µl of a solution containing biotinylated detection antibodies specific 
to the cytokines was added for 2 h at room temperature. The wells were washed again and filled with a solution 
containing streptavidin horseradish peroxidase for 45 min at room temperature. Then, 100 µl of 
tetramethylbenzidine chromogen solution was added for 10-20 min in the dark. The reaction was stopped by 
adding 50 µl of 1 M H2SO4. The amount of substrate converted to products was thereafter detected as the optical 
density at 450 nm in an ELISA reader (Multiscan Ascent, Thermo Labsystems, Helsinki, Finland). The 
sensitivities of our assays were 6 pg/ml for IL-4, 6 pg/ml for IL-6,4 pg/ml for IL-10, 6 pg/ml for TNF-α and 7 
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pg/ml for IFN-γ. 
Statistical Analysis 
Blood cell counts as well as cytokine levels were expressed as medians (range), unless otherwise stated. 
Comparisons between the four groups were performed by Kruskal-Wallis test (non-parametric ANOVA) 
followed, in the case of significance, by Dunn's multiple-comparison test. A p value <0.05 was considered 
statistically significant. 
 
Table 1. Demographic, functional, airway inflammatory and treatment characteristics according to ACQ scores 
 Non-atopic healthy 
subjects  
(n = 22) 
Atopic 
non-asthmatics 
(n = 10) 
Asthmatics with 
ACQ <1.5  
(n = 20) 
Asthmatics with  
ACQ ≥1.5  
(n = 20) 
Age, years 42 ± 13 33 ± 10 43 ± 19 40 ± 16 
Males/females 13/9 5/5 13/7 7/13 
Tobacco status     
    Never smoked 12 1 17 12 
    Ex-smoker 5 6 2 2 
    Current smoker 5 3 1 6 
BMI 24 ± 3 23 ± 3 25 ± 5 28 ± 7c 
Positive skin prick test 0 10 20 20 
NO, ppb - 11 (6-27) 20 (5-222) 55 (8-165)c 
IgE, kU/l - 63 (21-303) 331 (56-1,670) 356 (37-2,532)c 
Sputum eosinophils, % 0 (0-3.6) 0 (0-4) 2.2 (0.4-19.4)a 8.8 (0-80.4)b,c 
Sputum neutrophils, % 38 (0-87) 23 (2-52) 40 (3-93) 40 (0-99) 
FEVb % 108 ± 16 103 ± 12 87 ± 19a 65 ± 17b,e,f 
FVC, % 111 ± 17 103 ± 12 97 ± 18 85 ± 16b 
FEV1/FVC, % 83 ± 8 85 ± 8 76 ± 15 65 ± 13b,d 
Reversibility, % - - 6.8 ± 4.5 21 ± 18d 
ACQ score - - 0.86 (0.49-1.28) 3.21 (2.07-4.58)e 
PC20M, mg/ml - - 3.09 (0.62-16) 0.83 (0.2-3.4) 
Oral CS 0 0 0 6 
Inhaled CS 0/22 0/10 9/20 19/20 
Inhaled CS, eq budesonide/day - - 0 (0-1,600) 2,000 (l,600-2,800)e 
LABA - - 9/20 17/20 
LTRA - - 3 11 
Theophylline - - - 6 
Results are expressed as means ± SD or numbers of patients, except PC20M, which is expressed as the geometric mean (range), and NO, 
IgE, ACQ score, inhaled corticosteroids and sputum neutrophils and eosinophils, which are expressed as medians (range). FVC = Forced 
vital capacity; BMI = body mass index; LABA = long acting β2-agonist; LTRA = leucotriene receptor antagonist; CS = corticosteroids. a p < 
0.01, b p < 0.001 versus non-atopic healthy subjects; c p < 0.05, d p < 0.01, e p < 0.001 versus atopic non-asthmatics; f p < 0.05 versus 
asthmatics with ACQ <1.5. 
 
Results 
Demographic, Lung Function, Airway Inflammation and Treatment Characteristics according to Asthma 
Control 
The subjects were well matched for their age and tobacco consumption. As expected, FEV1 values were clearly 
different (65 ± 17% pred.) in the group with ACQ score ≥1.5 when compared to the group with ACQ score <1.5 
(87 ± 19% pred.; p < 0.05) and to atopic non-asthmatics and non-atopic healthy subjects (p < 0.001 for both). 
Similarly forced vital capacity was also significantly decreased in the uncontrolled asthma group as compared to 
non-atopic healthy subjects, and the ratio of FEV1 to forced vital capacity was also significantly lower in 
uncontrolled asthmatics (65 ± 13%) than in non-atopic healthy subjects (83 ± 8%; p < 0.001) and atopic non-
asthmatics (85 ± 8%; p < 0.01). 
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It is also of interest to note that patients with an ACQ score ≥1.5 were taking higher doses of inhaled 
corticosteroids (2,000 eq budesonide/day range 1,600-2,800) in comparison with patients with an ACQ score 
<1.5 (0 eq budesonide/day range 0-1,600). Nine out of 20 controlled asthmatics and 17 out of 20 uncontrolled 
asthmatics were receiving inhaled long-acting β2-agonists. Some uncontrolled asthmatics were also taking oral 
corticosteroids (6/20), leucotriene receptor antagonists (11/20) or theophylline (6/20). 
Controlled and uncontrolled asthmatics exhibited higher sputum eosinophil counts than non-atopic healthy 
subjects (p < 0.01 and p < 0.001, respectively), while uncontrolled patients also had a greater sputum eosinophil 
count than atopic non-asthmatics (p < 0.05; table 1). 
 
Table 2. Blood cell counts 
 Non-atopic healthy 
subjects 
Atopic non-asthmatics Asthmatics  
with ACQ <1.5 
Asthmatics  
with ACQ ≥1.5 
Leucocytes, /µl 6,410 (4,200-12,200) 6,390 (4,000-7,490) 7,770 (5,430-13,280)d 8,690 (5,860-18,130)b,f 
Neutrophils, % 52 (41-73) 49 (42-75) 55 (41-84) 58 (33-90) 
Neutrophils, /µl 3,564 (2,088-5,914) 3,300 (1,760-5,230) 4,025 (2,850-11,100) 4,720 (2,380-15,190)b,d 
Lymphocytes, % 35 (19-47) 40 (19-47) 33 (9-41)c,f 26 (9-42)g 
Lymphocytes, /µl 1,918 (598-3,546) 1,940 (1,270-2,930) 2,250 (1,230-3,950) 2,360 (810-3,670) 
Monocytes, % 6.1 (4.7-11.5) 8.5 (4.3-11.2) 5.6 (3.9-10.6) 5.7 (0.7-9) 
Monocytes, /µl 404 (256-1,014) 460 (300-810) 430 (300-790) 445 (60-1,190) 
Eosinophils, % 1.7 (0.7-6.3) 1.7 (0.4-4.3) 4.3 (0.6-8.8) 3.8 (0.1-21) 
Eosinophils, /µl 120 (30-370) 90 (30-190) 315 (70-650)a,d 350 (9-l,350)a,d 
Basophils, % 0.7 (0.4-1.5) 0.5 (0.1-0.9) 0.7 (0.2-1.6) 0.6 (0-1.9) 
Basophils, µl 45 (21-98) 30 (10-60) 55 (10-150) 75 (20-150)e 
Results are expressed as medians (range). a p < 0.05, b p < 0.01, c p < 0.001 versus non-atopic healthy subjects; d p < 0.05, e p < 0.01, f p < 
0.001 versus atopic non-asthmatics; g p < 0.001 versus asthmatics with ACQ <1.5. 
 
Table 3. Cytokine production from a standardized blood volume 





with ACQ <1.5 
Asthmatics  
with ACQ ≥1.5 
IL-4, pg/ml RPMI 0 (0-9) 32 (0-169)b 16 (0-57)b 12 (0-349)b 
 PHA 61 (6-176) 172 (11-276)a 70 (21-171) 120 (7-761) 
 LPS 0 (0-24) 17 (0-171)a 28 (0-98)b 43 (0-541)b 
IL-6, pg/ml RPMI 0 (0-152) 0 (0-24) 0 (0-264) 0 (0-1,421) 
 PHA 81 (0-492) 36 (0-471) 86 (0-2,362) 58 (0-1,754) 
 LPS 307 (14-1,472) 184 (96-649) 311 (20-1,123) 167 (1-1,760) 
IL-10, pg/ml RPMI 0 (0-6) 9 (0-138) 1 (0-45) 0 (0-430) 
 PHA 321 (72-696) 172 (90-404) 212 (57-657) 328 (35-1,681) 
 LPS 487 (83-832) 289 (98-842) 470 (187-1,346) 684 (14-2,388)c 
IFN-γ, pg/ml RPMI 0 (0-239) 0 (0-39) 0 (0-57) 7 (0-89) 
 PHA 684 (25-2,972) 1,001 (124-2,503) 413 (31-1,630) 398 (123-1,407) 
 LPS 54 (0-936) 60 (0-1,145) 53 (7-398) 31 (0-238)a,d 
TNF-α, pg/ml RPMI 42 (0-793) 0 (0-110) 64 (0-1,403) 50 (0-2,733) 
 PHA 1,993 (666-7,552) 1,160 (739-2,338) 1,610 (928-7,536) 2,269 (267-4,654) 
 LPS 2,350 (1,140-5,755) 1,649 (1,370-2,754) 2,509 (592-5,995) 2,571 (80-5,052) 
Results are expressed as medians (range). Values for LPS and PHA represent the raw data as they were measured from ELISA without 
subtracting RPMI results. a p < 0.05, b p < 0.001 versus non-atopic healthy subjects; c p < 0.05 versus atopic non-asthmatics; d p = 0.06. 
Blood Cell Counts 
Asthmatics with an ACQ score > 1.5 had a greater total blood cell count compared to non-atopic healthy subjects 
(p < 0.01) and atopic non-asthmatics (p < 0.001). 
Both groups of asthmatics exhibited significantly raised systemic absolute eosinophil counts when compared to 
atopic non-asthmatics and non-atopic healthy subjects (p < 0.05 for both). 
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The absolute neutrophil count was significantly increased in the uncontrolled group when compared to non-
atopic healthy subjects and atopic non-asthmatics (p < 0.01 and p < 0.05, respectively). 
There was no difference between controlled and uncontrolled asthmatics apart from the percentage of 
lymphocytes, which was lower in uncontrolled asthmatics (p < 0.001; table 2). 
Cytokine Production from Blood Cell Culture  
The results regarding cytokine production from blood cells are given in table 3. 
Both groups of asthmatics and the atopic non-asthmatics were characterized by a significantly raised 
spontaneous IL-4 production (p < 0.001 for the three groups). Likewise, controlled and uncontrolled asthmatics 
also exhibited raised IL-4 production after stimulation by LPS when compared to atopic non-asthmatics (p < 
0.05 for both) and non-atopic healthy subjects (p < 0.05 and p < 0.01, respectively; fig. 1). 
IL-4 measured after LPS stimulation in atopic non-asthmatics was also greater than in non-atopic healthy 
subjects (p < 0.05), although there was no evidence of a real response to LPS in this case, the production of IL-4 
being quite similar to that seen with RPMI alone (table 3). After stimulation by PHA, only atopic non-asthmatics 
exhibited raised IL-4 production when compared to non-atopic healthy subjects (p < 0.05). 
Fig. 1. LPS-induced IL-4 (a) and IFN-γ (b) production from blood leucocytes in non-atopic healthy subjects 
(NAHS), atopic non-asthmatics (ANA), controlled asthmatics (CA; ACQ score <1.5) and uncontrolled 
asthmatics (UA; ACQ score ≥1.5). Each point represents the subtraction of LPS - RPMI for IL-4 and IFN-γ. 
Zero values were transformed to 1 for graphic representation. The bars represent the median. 
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Fig. 2. Effect of prednisolone (in M) on IFN-γ from blood leucocytes in healthy subjects and patients with 
difficult-to-control asthma. Each line represents 1 patient; healthy subjects are represented by squares and 
continuous lines and patients with difficult-to-control asthma by circles and dashed lines. Results are expressed 
as a percentage of baseline. 
 
 
The group with uncontrolled asthma showed lower release of IFN-γ following LPS exposure when compared to 
non-atopic healthy subjects (p < 0.05; fig. 1) and controlled asthmatics (p < 0.05). Uncontrolled asthmatics also 
differed from atopic healthy subjects in terms of increased IL-10 production (table 3). There was no significant 
difference between the groups with regard to the production of other cytokines. 
In the controlled asthma group, there were no significant differences regarding cytokine production between 
those who were steroid naïve (n = 12) and those regularly receiving inhaled corticoids (n = 8). We did not find 
any relationship between the dose of inhaled corticosteroids received by the patients and the level of IFN-γ 
production (r = -0.2, p = 0.21). 
The effect of prednisolone on IFN-γ production from blood cells was assessed in vitro in a pool of healthy 
subjects and patients with difficult-to-control asthma (n = 10). At 10-9, 10-8 and 10-7 M, it produced significant 
inhibition of 48 ± 12% (p < 0.01), 63 ± 10% (p < 0.001) and 68 ± 10% (p < 0.0001), respectively (fig. 2). 
Discussion 
Our study shows that endotoxin-induced cytokine release from blood leucocytes reveals a clear Th2 pattern in 
asthmatics and atopic non-asthmatics as compared to non-atopic healthy subjects. In particular, LPS-induced IL-
4 release was clearly increased in controlled and uncontrolled asthmatics when compared to non-atopic healthy 
subjects. By contrast, uncontrolled asthmatics displayed a strikingly decreased production of IFN-γ in response 
to endotoxin as compared to non-atopic healthy subjects. 
Although greater in asthmatics than in healthy subjects, the blood eosinophil count was not associated with 
uncontrolled asthma, which is different from results we recently reported for sputum eosinophilia [12]. Blood 
neutrophilia was raised in uncontrolled asthmatics as compared to atopic non-asthmatics and non-atopic healthy 
subjects but did not distinguish controlled from uncontrolled asthmatics. 
The raised spontaneous production of IL-4 seen in asthmatics and atopic non-asthmatics supports the pivotal role 
of Th2-driven inflammation in atopic diseases [18]. It has been clearly demonstrated that stimulation of 
peripheral blood monuclear cells (PBMC) in vitro with an allergen resulted in greater release of IL-4 in 
sensitized subjects [19]. Our study expands this finding by using endotoxin as another type of environmental 
stimulus. Although endotoxin is rather considered to favour a Th1 pathway accompanied by neutrophilic 
inflammation [7], our results show that endotoxin enhances IL-4 release from circulating leucocytes in 
asthmatics but not in atopic non-asthmatics nor in non-atopic healthy subjects. 
This finding indicates that amplification of Th2 cytokine release from leucocytes following endotoxin exposure 
is restricted to atopic asthmatics but did not distinguish controlled from uncontrolled asthmatics. Remarkably, 
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there was no relationship between the level of asthma control and spontaneous IL-4, which is a hallmark of atopy 
rather than of asthma. 
Our results are in keeping with those of Magnan et al. [20], who, using the same whole-blood model, found that 
IL-4 release was more dependent on atopy than on asthma. Interestingly, circulating leucocytes from non-atopic 
healthy subjects, the large majority of whom failed to spontaneously release IL-4, were also largely unable to 
release this cytokine after stimulation with LPS. In this respect, IL-4 behaves differently from other cytokines 
like IL-6, IL-10 or IFN-γ, which, although not spontaneously produced by the majority of healthy subjects, are 
clearly released following exposure to LPS. In contrast to LPS, PHA induces IL-4 production by leucocytes from 
healthy subjects. This shows that healthy subjects are perfectly capable of producing this Th2 cytokine under 
certain circumstances. In our study, atopic non-asthmatics were particularly prompt in releasing IL-4 in response 
to PHA. 
As we worked on a whole-blood model including all types of leucocytes, cells involved in IL-4 release may 
differ according to the type of stimulus. While T lymphocytes are recognized to be strongly activated by the 
polyclonal activator PHA and are probably the main source of IL-4 after PHA stimulation [21], release of IL-4 
following LPS is perhaps more dependent on the granulocyte fraction, as eosinophils [22] and basophils [23] are 
also able to release this cytokine. Whichever the mechanisms, it is clear that asthmatics, and in particular patients 
with difficult-to-control asthma, still exhibit raised IL-4 release despite heavy treatment with inhaled and 
sometimes oral corticoids, a class of drug that shows a convincing inhibitory effect on IL-4 production both in 
vitro [24, 25] and in vivo [24, 26]. 
In contrast to what was found for IL-4, uncontrolled asthmatics differed from non-atopic healthy subjects in 
terms of a diminution of IFN-γ production following LPS exposure, which points to a deficiency of the Th1 
pathway in response to this bacterial product in the more severe types of asthma. Treatment with a high dose of 
inhaled corticoids or oral corticoids may play a role in this reduction of IFN-γ release, as we found that 
prednisolone inhibited IFN-γ release from blood leucocytes in vitro in a similar way to that reported by Braun et 
al. [24] from PBMC. However, the impact of treatment with corticoids on IFN-γ production in vivo is highly 
controversial [26, 27]. In addition, the fact that, in the group with well-controlled asthma, patients taking inhaled 
corticoids failed to differ from their steroid-naive counterparts suggests that inhaled corticoids might not be the 
main reason for the reduced production of IFN-γ seen in our patients with difficult-to-control asthma. Moreover 
we did not find a relationship between the dose of inhaled corticoids and the level of IFN-γ produced in 
asthmatics. Our finding is in keeping with the literature, although the methodology used may differ between 
studies. Peripheral blood cells from children with both mild and moderate-to-severe atopic asthma were found to 
release less IFN-γ than those of healthy children when stimulated by lectins like concanavalin A or PHA [28,29]. 
Furthermore, Leonard et al. [19] found that, in adult subjects, IFN-γ release from PBMC following allergen 
stimulation in vitro was lower than in atopic non-asthmatics and healthy subjects. Additionally, in that study, 
IFN-γ release was inversely related to symptom score in asthmatics [19]. As for the consequences of impaired 
IFN-γ production, it is important to mention that IFN-γ is a type 2 IFN involved in host defence against micro-
organisms [30]. It is believed that some difficult-to-control asthma may be linked to persistent infection [31]. In 
view of this, impaired IFN-γ production in response to LPS may be an immunological feature that can make 
asthmatics prone to chronic infection [8, 32]. 
In conclusion, stimulation of blood leucocytes by endotoxin enhances IL-4 release in controlled and uncontrolled 
atopic asthmatics, which differentiates atopic asthmatics from atopic non-asthmatics and non-atopic healthy 
subjects. In addition, it reveals an impairment of IFN-γ production selectively observed in uncontrolled 
asthmatics. This impairment of IFN-γ release combined with increased secretion of IL-4 highlights the strongly 
skewed immune response towards the Th2 pattern following endotoxin stimulation in difficult-to-control asthma. 
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